Relationship between CSF tau biomarkers and structural brain MRI measures in frontotemporal lobar degeneration.


Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
15 11 2022
Historique:
received: 03 03 2022
revised: 08 08 2022
accepted: 05 09 2022
pubmed: 18 9 2022
medline: 28 10 2022
entrez: 17 9 2022
Statut: ppublish

Résumé

Recently in the field neurodegenerative diseases increasing attention has been pointed to CSF biomarkers and their integration with neuroimaging (1). Frontotemporal lobar degeneration (FTLD) refers to a heterogeneous group of clinical syndromes with different underlying proteinopathies including tau pathology. CSF biomarkers have been proposed as diagnostic and prognostic factors. Aim of our study was to evaluate the relationship between CSF tau biomarkers and structural MRI brain measures in FTLD. We included early FTLD patient. All included patients underwent lumbar puncture to evaluate amyloid, total-tau (t-tau), phospho-tau 181 (p-tau); p-tau/t-tau ratio was also calculated; brain MRI was performed to estimate whole brain volume, volume of principal deep grey matter structures and regional cortical thickness. Demographic characteristics of the 28 included patients were as follows: female/male: 9/19; mean ± SD age: 68.1 ± 7.8 years. The p-tau/t-tau ratio was significantly correlated with whole brain volume (r = 0.69; p: 0.001), left putamen volume (r = 0.55 p: 0.009), left pallidum volume (r = 0.41; p: 0.01), right accumbens area (r = 0.47; p: 0.02). P-tau/t tau ratio showed also a significant correlation with cortical thickness of left temporal lobe (r = 0.74; p: 0.001) and right lateral orbital frontal cortex (r = 0.45; p: 0.03). Linear regression showed a significant relationship between p-tau/t-tau ratio and left temporal pole (p = 0.01; r Our data suggest that CSF biomarkers, especially p-tau/t-tau ratio, could play a role as prognostic factor in FTLD. Further longitudinal investigations are needed to confirm these findings.

Sections du résumé

BACKGROUND
Recently in the field neurodegenerative diseases increasing attention has been pointed to CSF biomarkers and their integration with neuroimaging (1). Frontotemporal lobar degeneration (FTLD) refers to a heterogeneous group of clinical syndromes with different underlying proteinopathies including tau pathology. CSF biomarkers have been proposed as diagnostic and prognostic factors. Aim of our study was to evaluate the relationship between CSF tau biomarkers and structural MRI brain measures in FTLD.
METHODS
We included early FTLD patient. All included patients underwent lumbar puncture to evaluate amyloid, total-tau (t-tau), phospho-tau 181 (p-tau); p-tau/t-tau ratio was also calculated; brain MRI was performed to estimate whole brain volume, volume of principal deep grey matter structures and regional cortical thickness.
RESULTS
Demographic characteristics of the 28 included patients were as follows: female/male: 9/19; mean ± SD age: 68.1 ± 7.8 years. The p-tau/t-tau ratio was significantly correlated with whole brain volume (r = 0.69; p: 0.001), left putamen volume (r = 0.55 p: 0.009), left pallidum volume (r = 0.41; p: 0.01), right accumbens area (r = 0.47; p: 0.02). P-tau/t tau ratio showed also a significant correlation with cortical thickness of left temporal lobe (r = 0.74; p: 0.001) and right lateral orbital frontal cortex (r = 0.45; p: 0.03). Linear regression showed a significant relationship between p-tau/t-tau ratio and left temporal pole (p = 0.01; r
CONCLUSIONS
Our data suggest that CSF biomarkers, especially p-tau/t-tau ratio, could play a role as prognostic factor in FTLD. Further longitudinal investigations are needed to confirm these findings.

Identifiants

pubmed: 36115219
pii: S0022-510X(22)00277-5
doi: 10.1016/j.jns.2022.120415
pii:
doi:

Substances chimiques

tau Proteins 0
Biomarkers 0
Amyloid beta-Peptides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

120415

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest regarding this research.

Auteurs

Giuseppe Fenu (G)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy. Electronic address: giusefenu@gmail.com.

Valentina Oppo (V)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Giulia Serra (G)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Lorena Lorefice (L)

Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.

Francesca Di Sfefano (F)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Dario Deagostini (D)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Cristina Mancosu (C)

Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.

Elisabetta Fadda (E)

Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.

Cristina Melis (C)

Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.

Paolo Siotto (P)

Radiology Unit, ARNAS Brotzu, Cagliari, Italy.

Eleonora Cocco (E)

Multiple Sclerosis Centre, University of Cagliari, Cagliari, Italy.

Maurizio Melis (M)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Giovanni Cossu (G)

Department of Neuroscience, ARNAS Brotzu, Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH